Micafungina Sala (Micafungin)

Micafungin inhibits the fungal enzyme 1,3‑β‑D‑glucan synthase, which is essential for synthesizing β‑glucan, a critical structural component of the fungal cell wall. Disruption of β‑glucan production weakens the cell wall, leading to osmotic instability and ultimately fungal cell death, while sparing human cells that lack this pathway.

The dosage of Micafungina Sala is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate intravenous infusion rate and duration according to current treatment guidelines.

The safety of micafungin in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Micafungina Sala belongs to the echinocandin class, which targets the fungal cell wall, unlike azoles that inhibit ergosterol synthesis. Echinocandins, including micafungin, are generally well‑tolerated and have activity against many azole‑resistant Candida strains, making them a valuable alternative for serious invasive infections.

Micafungina Sala should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and discoloration, and it should be administered promptly after preparation.

Micafungina Sala is given as an intravenous infusion. The preparation is diluted in an appropriate compatible solution and infused over the time period recommended by the prescribing clinician, typically ranging from 30 minutes to an hour, depending on the clinical protocol.

Serious adverse events include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, renal impairment, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of liver dysfunction, allergic responses, and renal changes throughout therapy.

Micafungina Sala is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving concomitant medications that pose a high risk of additive toxicity.